©2024 Stanford Medicine
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
Not Recruiting
Trial ID: NCT02695628
Purpose
This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission
tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in
imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks
blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor.
[18F]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that
have a low level of oxygen, and the radiation given off by [18F]FMISO is picked up by a PET
scan and this may help researchers learn whether changes occur in the tumors after treatment,
which can help decide how well the treatment worked earlier than is currently possible
Official Title
Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT
Stanford Investigator(s)
Rajesh Shah
Clinical Associate Professor, Radiology
Eligibility
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histopathologic or imaging and clinical features of tumor(s) diagnostic for
hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features
diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and
Data System (LIRADS) 4 or greater
- Total bilirubin < 3.0
- Child Pugh A or B
- Tumor amenable to transcatheter arterial embolization
- Able to provide informed consent
Exclusion Criteria:
- Uncontrolled large ascites
- Main or segmental portal vein thrombosis
- Locoregional treatment of hepatocellular carcinoma within the prior 3 months or
chemotherapy within the previous 3 months
- Inability or contraindication to undergo transcatheter arterial embolization
- Inability to lay flat for at least 2 consecutive hours
- Severe acute illness
- Uncontrolled chronic illness such as hypertension, diabetes, or heart failure
- Contraindication to CT or MRI contrast
- Pregnancy
Intervention(s):
procedure: Arterial Embolization
drug: 18F-Fluoromisonidazole
diagnostic test: Computed Tomography
diagnostic test: Positron Emission Tomography
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061